AU2021320233A1 - IL10Ra binding molecules and methods of use - Google Patents
IL10Ra binding molecules and methods of use Download PDFInfo
- Publication number
- AU2021320233A1 AU2021320233A1 AU2021320233A AU2021320233A AU2021320233A1 AU 2021320233 A1 AU2021320233 A1 AU 2021320233A1 AU 2021320233 A AU2021320233 A AU 2021320233A AU 2021320233 A AU2021320233 A AU 2021320233A AU 2021320233 A1 AU2021320233 A1 AU 2021320233A1
- Authority
- AU
- Australia
- Prior art keywords
- il10ra
- binding
- cell
- binding molecule
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063061562P | 2020-08-05 | 2020-08-05 | |
| US63/061,562 | 2020-08-05 | ||
| US202063078745P | 2020-09-15 | 2020-09-15 | |
| US63/078,745 | 2020-09-15 | ||
| US202163136098P | 2021-01-11 | 2021-01-11 | |
| US202163135884P | 2021-01-11 | 2021-01-11 | |
| US63/135,884 | 2021-01-11 | ||
| US63/136,098 | 2021-01-11 | ||
| PCT/US2021/044603 WO2022031885A2 (en) | 2020-08-05 | 2021-08-05 | Il10ra binding molecules and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2021320233A1 true AU2021320233A1 (en) | 2023-03-23 |
| AU2021320233A2 AU2021320233A2 (en) | 2023-05-25 |
Family
ID=92302013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021320233A Pending AU2021320233A1 (en) | 2020-08-05 | 2021-08-05 | IL10Ra binding molecules and methods of use |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12297281B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4192852A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7767391B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230061394A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116322754A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021320233A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3190427A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022031885A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7641912B2 (ja) | 2019-04-19 | 2025-03-07 | シナーキン・ファーマ・ベスローテン・フエンノートシャップ | Il13を含む融合タンパク質 |
| US12540188B2 (en) * | 2020-08-05 | 2026-02-03 | Synthekine, Inc. | IL10Rα/IL2Rγ synthetic cytokines |
| WO2022031885A2 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il10ra binding molecules and methods of use |
| JP7743500B2 (ja) | 2020-08-05 | 2025-09-24 | シンセカイン インコーポレイテッド | Il10受容体結合性分子および使用方法 |
| WO2023102493A2 (en) * | 2021-12-01 | 2023-06-08 | Synthekine, Inc. | Il10 variants and uses thereof |
| KR20240114801A (ko) * | 2023-01-17 | 2024-07-25 | 한양대학교 산학협력단 | Il-10 수용체에 특이적으로 결합하는 항체 및 이의 용도 |
| TW202444757A (zh) * | 2023-03-14 | 2024-11-16 | 美商奧迪希治療公司 | 抗cd25抗原結合蛋白及其用途 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7198919B1 (en) | 1983-04-25 | 2007-04-03 | Genentech, Inc. | Use of alpha factor sequences in yeast expression systems |
| US4569794A (en) | 1984-12-05 | 1986-02-11 | Eli Lilly And Company | Process for purifying proteins and compounds useful in such process |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5439829A (en) | 1991-01-30 | 1995-08-08 | Eli Lilly And Company | Immobilization of biologically active molecules by changing the Oxidation state of a chelated transition metal ion |
| CA2113990A1 (en) | 1991-07-26 | 1993-02-18 | Frederick L. Moolten | Cancer therapy utilizing malignant cells |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US5320663A (en) | 1992-07-02 | 1994-06-14 | E. I. Du Pont De Nemours And Company | Method of obtaining lead and organolead from contaminated media using metal accumulating plants |
| US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
| WO1995002698A1 (en) | 1993-07-12 | 1995-01-26 | Life Technologies, Inc. | Composition and methods for transfecting eukaryotic cells |
| US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
| US5650234A (en) | 1994-09-09 | 1997-07-22 | Surface Engineering Technologies, Division Of Innerdyne, Inc. | Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US8921528B2 (en) | 2004-06-01 | 2014-12-30 | Domantis Limited | Bispecific fusion antibodies with enhanced serum half-life |
| JP2008501706A (ja) | 2004-06-04 | 2008-01-24 | ジェネンテック・インコーポレーテッド | 疾患の治療方法 |
| US7553932B1 (en) * | 2005-04-25 | 2009-06-30 | La Jolla Institute For Allergy And Immunology | Methods of treating viral infection with IL-10 receptor antagonists |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| DE602006009834D1 (de) | 2005-09-01 | 2009-11-26 | Schering Corp | Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung |
| DK2046809T3 (en) | 2006-07-19 | 2017-03-13 | Univ Pennsylvania | WSX-1 / IL-27 AS A TARGET OBJECTIVE FOR ANTI-INFLAMMATORY REACTIONS |
| CN101952312A (zh) * | 2007-07-31 | 2011-01-19 | 米迪缪尼有限公司 | 多特异性表位结合蛋白及其应用 |
| CA2706425A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Method for obtaining polypeptide constructs comprising two or more single domain antibodies |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| JP2011524741A (ja) | 2008-05-27 | 2011-09-08 | 協和発酵キリン株式会社 | インターロイキン10受容体(il−10r)抗体及び使用方法 |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| WO2010118243A2 (en) | 2009-04-08 | 2010-10-14 | Genentech, Inc. | Use of il-27 antagonists to treat lupus |
| WO2010142551A2 (en) | 2009-06-12 | 2010-12-16 | Ablynx N.V. | Single variable domain (vhh) antibodies to cytokines of the il-17 receptor family |
| GB201005063D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| WO2011133886A2 (en) * | 2010-04-23 | 2011-10-27 | Genentech, Inc. | Production of heteromultimeric proteins |
| UY33492A (es) | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| US20120201746A1 (en) | 2010-12-22 | 2012-08-09 | Abbott Laboratories | Half immunoglobulin binding proteins and uses thereof |
| DK2714738T3 (en) | 2011-05-24 | 2019-01-28 | Zyngenia Inc | MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS |
| EP2729488A4 (en) | 2011-07-06 | 2015-01-14 | Medimmune Llc | PROCESS FOR PREPARING MULTIMANT POLYPEPTIDES |
| WO2013059299A1 (en) | 2011-10-17 | 2013-04-25 | The Uab Research Foundation | Antibodies for interferon subtypes and interferon/interferon receptor ternary complex and uses thereof |
| CN103906533A (zh) | 2011-11-07 | 2014-07-02 | 米迪缪尼有限公司 | 多特异性和多价结合蛋白及其用途 |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| JP6693872B2 (ja) | 2013-07-25 | 2020-05-13 | シトムクス セラピューティクス,インコーポレイティド | 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法 |
| US20160251440A1 (en) | 2013-09-26 | 2016-09-01 | Ablynx N.V. | Bispecific nanobodies |
| CN122399016A (zh) | 2014-03-15 | 2026-07-17 | 诺华股份有限公司 | 使用嵌合抗原受体治疗癌症 |
| IL300029A (en) | 2014-05-16 | 2023-03-01 | Baylor Res Institute | Methods and preparations for the treatment of autoimmune and inflammatory conditions |
| AU2015366284B2 (en) | 2014-12-19 | 2021-07-22 | Ablynx N.V. | Cysteine linked nanobody dimers |
| HRP20191800T1 (hr) | 2015-05-13 | 2019-12-27 | Ablynx N.V. | Polipeptidi koji regrutiraju t stanice koji se temelje na tcr alfa/beta reaktivnosti |
| EP3297672B1 (en) | 2015-05-21 | 2021-09-01 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| PT3328894T (pt) | 2015-08-06 | 2019-02-13 | Agency Science Tech & Res | Anticorpos de cadeia comum gama/il2rbeta |
| CN107216389B (zh) | 2016-03-18 | 2022-03-29 | 和迈生物科技有限公司 | 抗pd-l1纳米抗体及其编码序列和用途 |
| CN107400166A (zh) | 2016-05-19 | 2017-11-28 | 苏州康宁杰瑞生物科技有限公司 | 针对ctla4的单域抗体及其衍生蛋白 |
| SG11201908929VA (en) | 2017-03-31 | 2019-10-30 | Univ Leland Stanford Junior | Synthekine compositions and methods of use |
| GB201707238D0 (en) | 2017-05-05 | 2017-06-21 | Univ Oxford Innovation Ltd | Composition |
| EP3634465A4 (en) | 2017-05-25 | 2021-01-20 | The Broad Institute, Inc. | LYMPHOCYTE ANTIGEN CD5 SIMILAR (CD5L) MONOMER, HOMODIMER AND INTERLEUKIN 12B (P40) HETERODIMER ANTAGONISTS AND METHOD OF USE THEREOF |
| WO2018222578A1 (en) | 2017-05-30 | 2018-12-06 | Agrivida, Inc. | Immunomodulating transgenic plants and related methods |
| WO2018233624A1 (zh) | 2017-06-20 | 2018-12-27 | 和迈生物科技有限公司 | 抗Her2纳米抗体及其编码序列和用途 |
| IL321812A (en) | 2017-08-03 | 2025-08-01 | Synthorx Inc | Cytokine complexes for the treatment of autoimmune diseases |
| SG11202004158QA (en) | 2017-12-28 | 2020-06-29 | Nanjing Legend Biotech Co Ltd | Single-domain antibodies and variants thereof against tigit |
| IL279367B2 (en) | 2018-06-13 | 2026-05-01 | Novartis Ag | BCMA chimeric antigen receptors and their uses |
| WO2020144164A1 (en) | 2019-01-07 | 2020-07-16 | Bactolife Aps | Pathogen binding proteins |
| GB201903767D0 (en) | 2019-03-19 | 2019-05-01 | Quadrucept Bio Ltd | Multimers, tetramers & octamers |
| CN111018985B (zh) | 2019-12-06 | 2021-06-18 | 南京融捷康生物科技有限公司 | 针对牛血清白蛋白bsa的单域抗体的应用 |
| WO2022031885A2 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il10ra binding molecules and methods of use |
| JP7743500B2 (ja) | 2020-08-05 | 2025-09-24 | シンセカイン インコーポレイテッド | Il10受容体結合性分子および使用方法 |
| US20250163162A1 (en) | 2021-01-11 | 2025-05-22 | Synthekine, Inc. | Compositions and methods related to receptor pairing |
-
2021
- 2021-08-05 WO PCT/US2021/044603 patent/WO2022031885A2/en not_active Ceased
- 2021-08-05 CN CN202180068625.XA patent/CN116322754A/zh active Pending
- 2021-08-05 KR KR1020237007568A patent/KR20230061394A/ko active Pending
- 2021-08-05 EP EP21853681.1A patent/EP4192852A4/en active Pending
- 2021-08-05 CA CA3190427A patent/CA3190427A1/en active Pending
- 2021-08-05 US US18/006,831 patent/US12297281B2/en active Active
- 2021-08-05 JP JP2023507869A patent/JP7767391B2/ja active Active
- 2021-08-05 AU AU2021320233A patent/AU2021320233A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230061394A (ko) | 2023-05-08 |
| JP2023536654A (ja) | 2023-08-28 |
| EP4192852A4 (en) | 2025-07-23 |
| AU2021320233A2 (en) | 2023-05-25 |
| US12297281B2 (en) | 2025-05-13 |
| CA3190427A1 (en) | 2022-02-10 |
| US20230272091A1 (en) | 2023-08-31 |
| CN116322754A (zh) | 2023-06-23 |
| JP7767391B2 (ja) | 2025-11-11 |
| WO2022031885A2 (en) | 2022-02-10 |
| WO2022031885A3 (en) | 2022-03-10 |
| EP4192852A2 (en) | 2023-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12077594B2 (en) | IL2RG binding molecules and methods of use | |
| US12234291B2 (en) | IL2RB binding molecules and methods of use | |
| US12297281B2 (en) | IL10RA binding molecules and methods of use | |
| US20230357424A1 (en) | Cd45 binding molecules and methods of use | |
| US20250333521A1 (en) | Il10rb binding molecules and encoding nucleic acids | |
| US20240376217A1 (en) | Il23r binding molecules and methods of use | |
| US12448457B2 (en) | GP130 binding molecules and methods of use | |
| US12018085B2 (en) | Interferon-gamma R2 (IFNGR2) binding molecules comprising single-domain antibodies and method of use thereof to treat autoimmune and inflammatory diseases | |
| US20230365696A1 (en) | Ifngr1 binding molecules and methods of use | |
| RU2858560C2 (ru) | Молекулы, связывающие gp130, и способы их применения | |
| CN121108347A (zh) | 抗ly6g6d抗体或其抗原结合片段及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 08 MAY 2023 |